An Early Phase Development, Partly Blinded, Positive and Vehicle Controlled, Randomized, Non-inferiority Investigation of the Pharmacokinetics, Safety and Efficacy of BB2603 Cutaneous Hand-Pump Spray versus Lamisil® Spray and versus BB2603 Vehicle Hand-Pump Spray in Subjects with Onychomycosis and associated Tinea Pedis.
Latest Information Update: 14 Jun 2022
At a glance
- Drugs Terbinafine (Primary)
- Indications Onychomycosis; Tinea pedis
- Focus First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Blueberry Therapeutics
- 01 Jun 2022 Results published in the Mycoses
- 21 Nov 2018 Results presented in a Blueberry Therapeutics Media Release.
- 21 Nov 2018 Status changed from recruiting to completed, according to a Blueberry Therapeutics media release.